Stock Track | Moderna Soars 5.05% as Analyst Downgrade Sparks Optimism

Stock Track

Feb 18, 2025

Moderna, Inc. (MRNA) stock surged 5.05% in pre-market trading on Tuesday. The biotech company's shares experienced a significant uplift following an analyst downgrade that highlighted potential upside factors.

Barclays downgraded Moderna to "Equal Weight" from "Overweight," citing policy risks and a lack of major clinical catalysts. However, the firm's assessment of Moderna's differentiated platform sparked investor optimism, fueling the stock's rally.

Despite the downgrade, analysts remain optimistic about Moderna's prospects, particularly in the rapidly evolving field of mRNA technology. The company's innovative approach and robust pipeline are expected to drive long-term growth and sustain its position as a leader in the biotech industry.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1175291830"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1175291830\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1175291830?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-18 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175291830","market":"hk","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.05% as Analyst Downgrade Sparks Optimism","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) stock surged 5.05% in pre-market trading on Tuesday. The biotech company's shares experienced a significant uplift following an analyst downgrade that highlighted potential upside factors.</p>\n\n<p>Barclays downgraded Moderna to \"Equal Weight\" from \"Overweight,\" citing policy risks and a lack of major clinical catalysts. However, the firm's assessment of Moderna's differentiated platform sparked investor optimism, fueling the stock's rally.</p>\n\n<p>Despite the downgrade, analysts remain optimistic about Moderna's prospects, particularly in the rapidly evolving field of mRNA technology. The company's innovative approach and robust pipeline are expected to drive long-term growth and sustain its position as a leader in the biotech industry.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.05% as Analyst Downgrade Sparks Optimism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.05% as Analyst Downgrade Sparks Optimism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-18 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) stock surged 5.05% in pre-market trading on Tuesday. The biotech company's shares experienced a significant uplift following an analyst downgrade that highlighted potential upside factors.</p>\n\n<p>Barclays downgraded Moderna to \"Equal Weight\" from \"Overweight,\" citing policy risks and a lack of major clinical catalysts. However, the firm's assessment of Moderna's differentiated platform sparked investor optimism, fueling the stock's rally.</p>\n\n<p>Despite the downgrade, analysts remain optimistic about Moderna's prospects, particularly in the rapidly evolving field of mRNA technology. The company's innovative approach and robust pipeline are expected to drive long-term growth and sustain its position as a leader in the biotech industry.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1175291830","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175291830","pubTimestamp":1739889765,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc.  stock surged 5.05% in pre-market trading on Tuesday. The biotech company's shares experienced a significant uplift following an analyst downgrade that highlighted potential upside factors.Barclays downgraded Moderna to \"Equal Weight\" from \"Overweight,\" citing policy risks and a lack of major clinical catalysts. However, the firm's assessment of Moderna's differentiated platform sparked investor optimism, fueling the stock's rally.Despite the downgrade, analysts remain optimistic a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"分析师下调评级引发乐观情绪，Moderna股价飙升5.05%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) stock surged 5.05% in pre-market trading on Tuesday. The biotech company's shares experienced a significant uplift following an analyst downgrade that highlighted potential upside factors.\nBarclays downgraded Moderna to \"Equal Weight\" from \"Overweight,\" citing policy risks and a lack of major clinical catalysts. However, the firm's assessment of Moderna's differentiated platform sparked investor optimism, fueling the stock's rally.\nDespite the downgrade, analysts remain optimistic about Moderna's prospects, particularly in the rapidly evolving field of mRNA technology. The company's innovative approach and robust pipeline are expected to drive long-term growth and sustain its position as a leader in the biotech industry.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}